Chemistry:Antazoline
 | |
| Clinical data | |
|---|---|
| Trade names | Vasocon-a |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | Topical (nasal, eye drops) |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C17H19N3 |
| Molar mass | 265.360 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Antazoline is a 1st generation antihistamine with anticholinergic properties used to relieve nasal congestion and in eye drops, usually in combination with naphazoline, to relieve the symptoms of allergic conjunctivitis.[1] To treat allergic conjunctivitis, antazoline can be combined in a solution with tetryzoline.[2] The drug is a Histamine H1 receptor antagonist:[3] selectively binding to but not activating the receptor, thereby blocking the actions of endogenous histamine and subsequently leading to the temporary relief of the negative symptoms brought on by histamine.
A large study on people 65 years old or older linked the development of Alzheimer's disease and other forms of dementia to the "higher cumulative" use of first-generation antihistamines, due to their anticholinergic properties.[4]
References
- ↑ "Effects of topically applied occular decongestant and antihistamine". American Journal of Ophthalmology 90 (2): 254–257. August 1980. doi:10.1016/s0002-9394(14)74864-0. PMID 7425039.
- ↑ "Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis". The Cochrane Database of Systematic Reviews 2015 (6): CD009566. June 2015. doi:10.1002/14651858.CD009566.pub2. PMID 26028608.
- ↑ "The suppression of olfactory bulbectomy-induced muricide by antidepressants and antihistamines via histamine H1 receptor blocking". Physiology & Behavior 51 (6): 1123–1127. June 1992. doi:10.1016/0031-9384(92)90297-f. PMID 1353628.
- ↑ "Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study". JAMA Internal Medicine 175 (3): 401–407. March 2015. doi:10.1001/jamainternmed.2014.7663. PMID 25621434.
 |  |
